The paper introduces PIFT, a framework that transfers peptide‑target interaction patterns to small molecules by jointly guiding masked discrete diffusion and continuous flow matching. PIFT maps peptide‑target and small‑molecule‑target interfaces into a shared, target‑conditioned interaction space, enabling peptide‑derived references to steer both building‑block logits and 3D coordinates toward peptide‑compatible molecules while maintaining a strong molecular prior. Experiments on diverse protein‑protein interaction targets demonstrate that this cross‑modal representation improves interface recovery, docking performance, and molecular properties.
By Jian Lee, Changyun Cho, Sun Kim
arXiv:2506. 14488v2 Announce Type: replace-cross Abstract: Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution.
By Dong Xu, Zhangfan Yang, Junchuang Cai, Sisi Yuan, Zexuan Zhu, Jianqiang Li, Junkai Ji
arXiv:2606. 23856v1 Announce Type: new Abstract: Generative molecular models for drug design are a promising direction with much active research.
By Konstantin Yatsenko, Arvind Thiagarajan
FuseDiff is an end‑to‑end diffusion model designed for dual‑target structure‑based drug design, jointly generating a ligand graph and two pocket‑specific binding poses conditioned on both target pockets. It employs a message‑passing backbone with Dual‑target Local Context Fusion (DLCF) to fuse ligand atom contexts from both pockets, preserving symmetry while enabling expressive joint modeling. The model enforces topological consistency across the two poses and allows target‑specific geometric adaptation, achieving state‑of‑the‑art docking performance and enabling systematic assessment of dual‑target pose quality before docking‑based pose search.
By Jianliang Wu, Anjie Qiao, Zhen Wang, Zhewei Wei, Sheng Chen
arXiv:2610.04850v2 Announce Type: replace
Abstract: Protein binding prediction is central to target identification, therapeutic binder design, and large scale screening, yet remains challenging becau...
By Jae Won Choi, Ryoonki Hong, Alan Liang, Manjula Adiveppa Wader, Bingsong Zeng, Peiyang Tang, Longwei Liu, Ruishan Liu
arXiv:2510.03095v4 Announce Type: replace
Abstract: Diffusion- and flow-based generative models have recently demonstrated strong performance in protein backbone generation tasks, offering unpreceden...
By Liyang Xie, Haoran Zhang, Zhendong Wang, Wesley Tansey, Mingyuan Zhou
arXiv:2607. 22143v1 Announce Type: new Abstract: Molecular glue degraders have emerged as a promising strategy for targeted protein degradation by inducing ternary complex formation between an E3 ubiquitin ligase and a target protein.
By Yuliang Yan, Shuo Yan, Haochun Tang, Yiqin Sun, Enyan Dai
arXiv:2512. 15133v3 Announce Type: replace-cross Abstract: Proteins inherently possess a consistent sequence-structure duality.
By Yi Zhou, Haohao Qu, Yunqing Liu, Shanru Lin, Le Song, Wenqi Fan
arXiv:2606. 01628v1 Announce Type: cross Abstract: Biomolecules such as proteins and small-molecule ligands play a central role in biological systems, arising from the tight interplay between sequence and three-dimensional structure.
By Keyue Qiu, Xintong Wang, Zhilong Zhang, Hao Zhou, Wei-Ying Ma
arXiv:2607. 18144v1 Announce Type: cross Abstract: Structure-based drug design (SBDD) leverages the 3D structure of protein targets, often complemented by other spatial constraints, to generate candidate binding molecules.
By Thomas MacDougall, Maksim Kuznetsov, Roman Schutski, Rim Shayakhmetov, Maxim Malkov, Vladimir Aladinskiy, Alex Aliper, Alex Zhavoronkov
arXiv:2606. 07567v1 Announce Type: cross Abstract: Protein function is largely determined by molecular surface geometry and physicochemical complementarity, yet most protein design methods condition only on backbone structure.
By Fang Wu, Shuting Jin, Xiangru Tang, Mark Gerstein, Xiangxiang Zeng, Yejin Choi, Jure Leskovec, Jinbo Xu
arXiv:2607. 12349v1 Announce Type: new Abstract: Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design.
By Ruoxi Gao, Jiangweizhi Peng, Ziqi Chen, Frazier N. Baker, David C. Kombo, John L. Kane Jr., Andrew A. Scholte, Yi Li, Matthew J. LaMarche, Luigi I. Iconaru, Hans-Peter Biemann, Mingyi Hong, Xia Ning